Editor
Medical Technology Stock Letter
John McCamant joined the Medical Technology Stock Letter as associate editor in 1987 and was named editor of this leading investment newsletter in August 2000. He has spent 25 years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, Mr. McCamant uncovered investment opportunities and guided investment strategy. At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, Bloomberg, and Marketwatch.
Nektar Therapeutics (NKTR), is a top pick for 2020, suggests John McCamant, an industry-leading biot...
After many years of fits & starts, 2020 will be the right year for Sangamo Therapeutics (SGMO), ...
Incyte (INCY) recently announced that the FDA has accepted for Priority Review the company’s n...
Zynerba (ZYNE) has been issued a US Patent titled “Treatment of Fragile X Syndrome with Cannab...